Overview of Hemor

Quick Facts

Property	Description
Active ingredients	Cinchocaine, Policresulen
Form	Ointment, Suppository
Pharmacological class	Local Anesthetic + Hemostatic/Antiseptic
Common use	Symptom relief and tissue support for anorectal issues
Origin	Synthetic Compound

Definition and Pharmaceutical Classification

Hemor is a compound pharmaceutical preparation specifically formulated as a topical anorectal medicine for localized application. It is defined as a combination drug because its therapeutic effect relies on the integration of two distinct active ingredients with complementary actions. The medication is typically available in two main dosage forms: a suppository and an ointment. This classification allows the medicine to bypass systemic circulation and deliver high concentrations of its agents exactly where they are needed, defining its role in targeted localized therapy.

Composition and Origin: Cinchocaine and Policresulen

Hemor contains the two main active ingredients, Cinchocaine and Policresulen, which are both synthetic compounds. Cinchocaine, the first component, belongs to the amide-type local anesthetic pharmacological class and is included for its powerful, long-acting ability to block pain sensations, a primary action for this class of drug. Policresulen, the second component, is a polycondensation product and is classified as a hemostatic agent (bleeding-stopper) and a broad-spectrum antiseptic. The clinical recognition of this combination formulation is based on the synergy between the numbing and tissue-supporting agents.

General Therapeutic Purpose and Dual Action

The overall purpose of Hemor is to provide immediate symptomatic relief while supporting the physical recovery of compromised tissue. This dual-action approach is a differentiating factor, contrasting with single-agent products that only manage pain or inflammation. Cinchocaine primarily addresses acute discomfort, such as localized pain and itching, by providing effective numbing action. Simultaneously, Policresulen exerts its astringent and coagulative properties to control minor localized bleeding and assist the natural regeneration of the epithelial lining. The drug is thus fundamentally designed to alleviate acute symptoms and facilitate tissue maintenance.

Regulatory References

Amide-Type Local Anesthetics Classification (NCBI Bookshelf)

What side effects are possible with Hemor?

Possible Side Effects and Safety Information

The regulatory safety profile for this Cinchocaine and Policresulen preparation is primarily defined by application-site reactions and specific safety constraints. Adverse reactions are classified according to frequency and the body system affected, consistent with official regulatory documentation.

Adverse Reactions and Frequencies

Localized discomfort is the most frequently documented adverse event. Reactions such as stinging, burning sensation, local irritation, and itching (pruritus) are described as occasional or transient events, often resolving shortly after application. More concerning reactions, including localized swelling, redness, and severe allergic contact sensitivity, are documented as isolated or rare occurrences.

Adverse effects fall primarily into the System-Organ-Classes of General Disorders and Administration Site Conditions and Skin and Subcutaneous Tissue Disorders.

Serious Safety Considerations

While systemic absorption is expected to be minimal with proper topical use, the regulatory label notes the potential for systemic effects of Cinchocaine, the local anesthetic component. These effects, which may include dizziness or nervous system reactions, are primarily relevant in cases of excessive application or accidental oral ingestion of the preparation. Skin sagging or atrophy is documented as a safety risk associated with prolonged or long-term use.

Population-Specific Constraints

Official documents detail specific constraints for certain patient populations. The preparation is not generally recommended for children under 12 years of age and carries specific safety concerns for those under 2. For pregnant or breastfeeding patients, use is advised only when strictly indicated following a professional risk assessment. Constraints also apply to individuals with severe hepatic impairment and those with existing systemic infections.

Overdose and Emergency Response

Overdose and When to Seek Help

The use of Hemor is generally localized; however, exposure to excessive amounts may lead to systemic absorption, primarily concerning the Cinchocaine component. Officially documented signs of overdose are consistent with Local Anesthetic Systemic Toxicity (LAST). These include Central Nervous System (CNS) manifestations such as seizure, agitation, altered mental status, dizziness, and sensory changes like perioral paresthesia and muscle twitching. Severe outcomes documented in regulatory sources are cardiac arrest, arrhythmias, hypotension, and acute respiratory depression.

Mandatory Emergency Response

Immediate medical attention must be sought for any suspected systemic toxicity or the appearance of severe symptoms. Regulators explicitly state that if a user has used too much ointment, they must tell their doctor. In the case of accidental oral ingestion of the preparation, official safety guidance mandates the user to immediately call a Poison Center. Specific procedural steps include rinsing the mouth and strictly not inducing vomiting.

Supportive Management and Monitoring

No specific antidote for this combination product is documented. Management is entirely symptomatic and supportive. This includes maintaining oxygenation, managing seizures, and treating severe hypotension. Hospital monitoring is required for systemic events, typically involving observation for a minimum of two hours for isolated neurological signs and four to six hours when cardiovascular involvement is present.

Therapeutic Uses of Hemor

What Hemor Treats: Main Uses and Benefits

The combination of active agents is commonly used for managing symptoms associated with primary anorectal conditions. Clinical areas of use include symptomatic hemorrhoids, anal fissures, and related inflammatory states like proctitis.

This medication is relevant for easing symptoms related to physical discomfort, including pain, burning, and severe itching, that frequently characterize acute flare-ups. It is also applied across domains where additional symptomatic support is needed, particularly when symptoms include minor superficial bleeding and swelling.

“The preparation is relevant for managing symptoms that interfere with daily comfort and supports patients during difficult episodes by easing distress.”

In clinical settings, it is often used during the post-operative phase following proctological surgery or when symptoms become temporarily overwhelming. This provides support that helps ease the overall symptom burden and contributes to improved day-to-day comfort during periods of heightened symptoms.

Quick Fact: Relief for Acute Anorectal Symptoms
Primary Domain	Symptomatic management of hemorrhoids and anal fissures
Benefit Focus	Easing pain, easing swelling, supporting symptom management
Typical Context	Acute flare-ups and post-operative care

Regulatory References

Indonesian National Agency of Drug and Food Control (BPOM) documentation

Eligibility and Restrictions for Use

Official Eligibility and Restrictions

The eligibility profile for Hemor, a combination topical medicine, is strictly defined by regulatory documentation across several domains, determining who is permitted to use the medicine under labeled conditions and who is formally excluded.

Eligibility Status
Populations Allowed	Adults (18 years and older) under standard label conditions.
Use Restricted	Patients who are pregnant or breastfeeding; use is conditional upon a formal benefit-risk assessment.

Age-Related Eligibility Rules

The medicine is contraindicated for use in children below two years of age. For the broader group of children and adolescents under 18 years, use is generally not recommended in the official prescribing information. Additionally, data concerning the safety and effectiveness of the Policresulen component in the geriatric population are documented as not established.

Contraindications and Comorbidities

Hemor is strictly contraindicated in patients with a known hypersensitivity or allergy to Cinchocaine, Policresulen, or any other components in the formulation. Use is further prohibited for individuals with severe liver impairment and restricted in cases of existing systemic infections. Caution is also advised regarding specific excipients, such as wool fat, for patients with a corresponding allergy.

This structure ensures adherence to population-based constraints documented by regulatory authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Regulatory Interaction Profile

The regulatory documentation for this combination topical medicine outlines potential interaction patterns primarily based on the systemic absorption risks of its local anesthetic component, Cinchocaine, and explicit local restrictions for the Policresulen component.

Pharmacodynamic and Additive Toxicity Interactions

Category	Documented Interaction Statement
CNS Depressants	Co-administration may increase the severity of CNS effects due to an additive pharmacodynamic effect, contingent upon systemic exposure of the Cinchocaine component.
Antiarrhythmic Drugs	Concurrent use of Class I Antiarrhythmic Drugs carries an increased risk of serious cardiovascular toxicity if significant systemic absorption occurs.
Methemoglobinemia Agents	The combination with other oxidizing or Methemoglobinemia-Inducing Agents increases the risk of this blood disorder through additive effects.

Local and Clearance Restrictions

Regulatory information includes specific constraints for local application. Co-administration of multiple topical products at the same site is restricted, and the use of irritating soaps on the affected area should be avoided. Furthermore, certain HIV medicines, such as Ritonavir and Cobicistat, have been identified as potentially increasing the effects of the local anesthetic ingredient.

In specific populations, the interaction profile notes an increased labeled risk of toxic plasma concentrations in patients with severe hepatic disease due to the component's reliance on liver metabolism for clearance.

Mechanism of Action

Hemor's mechanism of action involves a multi-targeted approach to influence local physiological processes. It acts across distinct mechanistic domains to influence pathways related to nerve signaling, inflammation, and vascular integrity, influencing pathways that result in specific physiological changes.

Interruption of Local Sensory Signaling

This domain focuses on the peripheral blockade of nerve impulse transmission. The anesthetic component targets voltage-gated sodium channels on nerve endings, preventing the rapid influx of sodium ions. This action stops the propagation of afferent sensory nerve impulses. This results in the interruption of sensory nerve signal transmission, directly modulating the activity of peripheral afferent nerve fibers.

Suppression of Inflammatory Cascades

This mechanism engages the Glucocorticoid Receptor to modulate inflammatory gene expression and inhibit key enzymes like Phospholipase A2. This action curtails the production of mediators in the arachidonic acid pathway, resulting in the downregulation of biological processes associated with vascular changes and fluid accumulation.

Modulation of Vascular and Structural Integrity

This domain involves stabilizing microvascular function and integrity through venoactive agents. The mechanism supports the enhancement of venous tone and restricts the leakage of fluid from capillary walls into the surrounding tissue. This results in a change in the local fluid balance and tissue volume, modulating the dynamics within the local vascular network.

Dosage and Administration Information

How Hemor is Used in Clinical Practice

This section describes the standard administration protocol for Hemor (Policresulen and Cinchocaine) regarding its application and usage frequency.

Administration Guidelines

Usage Parameter	Instruction
Approved Forms	Ointment (50 mg Policresulen / 10 mg Cinchocaine per 1 g) and Suppository (100 mg Policresulen / 2.5 mg Cinchocaine per unit).
Routes of Use	Topical (external application) or Rectal (internal application).
Dosing Frequency	Ointment is applied two to three times daily. Suppositories are typically administered once daily.
Course Duration	Use is generally restricted to a short-term period, often cited as up to seven days.

Procedural Administration Requirements

Specific conditions apply for the proper application of the medication. For internal rectal administration, the ointment is used with the enclosed applicator/cannula. The rectal form is preferably administered after a bowel movement to facilitate effective application. For internal ointment use, prior evacuation of the bowel is required. The product is exclusively intended for application to the region of the rectum and anus. The preparation is not recommended for use in individuals under 18 years of age.

These parameters define the standardized approach for the administration of Hemor regarding route, frequency, and preparation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hemor

Research available for this combination medicine, as summarized in scientific reviews, primarily describes symptomatic patterns observed in patients with acute anorectal conditions. The scientific literature often consists of observational data and reviews, with a limited number of controlled trials available for certain specific contexts. The information presented here summarizes the type of research that has been conducted and the limitations noted by researchers.

Evidence for Symptomatic Management of Anorectal Conditions

Research for the most common uses, such as symptomatic management of hemorrhoids, anal fissures, and related inflammatory states, has utilized analytical reviews that summarize patterns observed across many patients. These summaries pool data from multiple multicenter studies, which are often described as observational-style case series.

Studies monitored patient and physician assessments of outcomes related to symptom expression and local effects. They focused on outcomes related to physical discomfort, exploring whether symptoms such as localized pain, minor bleeding, itching, and burning were affected during the short term. This means the research reports observed short-term symptom patterns in these populations, but comparative evidence from controlled trials is limited. The overall certainty of the evidence remains low, as there is a documented lack of high-quality Randomized Controlled Trials (RCTs) directly comparing this combination medicine against a placebo.

Evidence for Use in Post-operative Symptom Support

Research has also explored the role of the product following surgical procedures, specifically examining pain intensity after open hemorrhoidectomy. At least one small, controlled, double-blinded RCT was evaluated in this research scenario. The study’s observations concerning the primary outcome (pain intensity) did not identify a pattern of difference between the group receiving the combination medicine and the groups receiving placebo or control. The sample sizes were modest, and the results apply only to the specific populations studied.

Limitations and Research Gaps

Follow-up durations were limited across the key studies and reviews, focusing largely on the acute phase of symptoms. Long-term outcomes remain uncharacterized, and data for extended-duration observation are sparse. Data for certain groups remain insufficient, and research is limited regarding the use of this medicine in specific populations, such as older adults or children. The evidence landscape indicates that controlled comparisons and long-term outcomes remain areas where further study is lacking.

Key Studies & References

Indonesian National Agency of Drug and Food Control (BPOM) documentation on the preparation for anorectal use

Frequently Asked Questions (FAQ)

Common questions about Hemor (FAQ)

Q: Is Hemor considered a pain reliever?

Yes, one of Hemor's two active ingredients is Cinchocaine, which belongs to the local anesthetic pharmacological class. According to official product information, this component is included to block pain sensations and provide effective numbing action for acute discomfort, functioning as a localized pain reliever.

Q: Is it common to feel tired after taking Hemor?

Hemor is intended for local application, and systemic absorption is expected to be minimal with proper use. However, regulatory information notes the potential for systemic effects of the Cinchocaine component, such as nervous system reactions, relevant in cases of excessive application or accidental oral ingestion. Tiredness is not listed as a common side effect for labeled use.

Q: Can Hemor affect sleep patterns?

The regulatory label documents the potential for nervous system reactions (Central Nervous System or CNS effects) from the anesthetic component in cases of misuse or excess application. Sleep disturbances are not explicitly listed as a frequent adverse event, but nervous system effects are a potential consideration described in the official warnings.

Q: Are there any long-term side effects linked to Hemor use?

Regulatory safety documents state that skin sagging or atrophy is documented as a safety risk associated with prolonged or long-term use of the preparation. Official research reviews also indicate that follow-up durations in clinical studies were limited, and long-term outcome data remains sparse in the available literature.

Q: Is it okay to have coffee while taking Hemor?

Official regulatory documents do not contain specific statements or warnings regarding the consumption of coffee or caffeine while using this medicine. The documented interactions are generally focused on co-administration with other medicines and local products.

Q: Can Hemor be taken by people with high blood pressure?

The regulatory interaction profile notes that concurrent use of certain Class I Antiarrhythmic Drugs is noted in the regulatory documents as carrying an increased risk of serious cardiovascular toxicity if significant systemic absorption of the anesthetic component occurs. High blood pressure (hypertension) itself is not listed as a direct contraindication for the intended topical use.

Q: What should be done if a dose of Hemor is missed?

The standard administration advice is to apply the next scheduled dose at the usual time. Official guidance recommends continuing to use the medicine as instructed by a healthcare provider.

Q: Is there a generic version of Hemor available?

Hemor is the brand name for a product containing Policresulen and Cinchocaine. Other products containing the same active ingredients may be available and marketed under different brand names in various regions, depending on local regulatory approval.

Q: Why do some people say Hemor didn't work for them?

Scientific literature reviews have noted research limitations, specifically a lack of high-quality Randomized Controlled Trials (RCTs) directly comparing the drug to a placebo. The documented research limitations may contribute to a variation in patient experience. For instance, observations concerning post-operative pain relief did not identify a pattern of difference between the group receiving the combination medicine and the control groups.

Q: What is the typical duration of effect for a dose of Hemor?

The local anesthetic component, Cinchocaine, is categorized as a long-acting anesthetic. Official information describes the duration of its pain-suppressing action as persistent, with effects typically lasting for several hours after application.

Q: Can Hemor be taken by people with kidney issues?

Constraints for individuals with severe hepatic (liver) impairment are noted because the anesthetic component is metabolized by the liver. Specific constraints for renal (kidney) issues are not listed as direct contraindications for this topical product in official documentation.

Q: Is Hemor available without a prescription?

The regulatory status of Hemor can vary by country. In many regions, the combination product is classified as a prescription-only medicine (Rx). Its status as a prescription-only medicine (Rx) is consistent with the drug authority's classification in many regions.

Q: What studies have been done on Hemor in different age groups?

Official research reviews indicate that clinical data for certain age groups are limited. Specifically, data regarding the safety and effectiveness of this medicine in older adults and children is noted as sparse or not established in the literature.

Q: Is Hemor used for any other purposes besides its main indication?

This combination product is officially approved for use in the symptomatic management of anorectal conditions such as hemorrhoids and anal fissures. Official regulatory documents only contain information regarding the approved uses for this combination product.

Q: Does Hemor cause weight gain or loss?

Adverse reactions documented in official regulatory documents are predominantly localized effects at the application site. Systemic changes like weight gain or loss are not listed among the commonly or rarely reported adverse events.

Q: How quickly should I expect to notice any effects from Hemor?

The local anesthetic component is quick-acting. The onset of its pain-suppressing action is typically observed within approximately 5 to 20 minutes after applying the medication.

Q: Is Hemor generally well-tolerated?

Based on the regulatory safety profile, the most frequently documented side effects are localized and transient reactions at the application site, such as stinging or irritation. More serious systemic events are documented as isolated or rare occurrences, primarily linked to misuse, such as excessive application or accidental ingestion.

Q: Why might a doctor prescribe Hemor over a non-drug therapy?

Hemor is defined by its dual-action approach, which provides both immediate pain relief via the anesthetic and local tissue support via the hemostatic agent. This combination of pharmacological effects distinguishes it from non-drug options that may target only one of these actions.

Q: Are headaches a common side effect of Hemor?

Regulatory documents classify adverse effects primarily into local administration site conditions. Headaches are not listed among the frequently documented or common local adverse events associated with the typical use of the topical preparation.

Q: Can Hemor cause stomach upset or nausea?

Adverse reactions documented in official regulatory documents are predominantly localized to the application site. Systemic adverse events like stomach upset or nausea are not listed as common or occasional side effects.

Q: Does Hemor make you more sensitive to the sun?

The documented adverse reactions for skin and subcutaneous tissue disorders are mainly localized to the site of application. Photosensitivity (increased sun sensitivity) is not listed in official regulatory documents as a recognized side effect of this combination product.

How should Hemor be stored and disposed of?

Official Storage and Disposal Requirements

Storage Condition	Requirement	Child-Safety	Disposal Rule
Temperature	Store below 25, C or 30, C, depending on the specific formulation; Do not freeze [Source 1.4, 1.5].	Keep out of the reach and sight of children [Source 1.4, 1.5].	Do not dispose in household waste or wastewater [Source 1.4].
Container/Protection	Keep in original packaging, protected from direct light and moisture [Source 1.4, 2.1].		Consult a pharmacist for instructions on discarding unused product [Source 1.4].

Official regulatory documents require that Hemor (Cinchocaine/Policresulen) be kept at controlled room temperature, protected from heat, light, and moisture to maintain product stability. The medication must remain in its original, tightly closed packaging and must not be used after the stated expiry date. A mandatory safety constraint requires storage out of the sight and reach of children. For disposal, official guidance strictly prohibits discarding the unused product into household trash or flushing it down the toilet, mandating consultation with a pharmacist for proper pharmaceutical waste handling.

Hemor